{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:35:15Z","timestamp":1780374915361,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,8,14]],"date-time":"2012-08-14T00:00:00Z","timestamp":1344902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s11523-012-0226-9","type":"journal-article","created":{"date-parts":[[2012,8,13]],"date-time":"2012-08-13T07:05:43Z","timestamp":1344841543000},"page":"183-188","source":"Crossref","is-referenced-by-count":30,"title":["Profiling mTOR pathway in neuroendocrine tumors"],"prefix":"10.1007","volume":"7","author":[{"given":"S.","family":"Cingarlini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Corbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,14]]},"reference":[{"issue":"1","key":"226_CR1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","volume":"12","author":"GV Thomas","year":"2006","unstructured":"Thomas GV, Tran C, Mellinghoff IK et al (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12(1):122\u2013127","journal-title":"Nat Med"},{"issue":"20","key":"226_CR2","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson CC, Liu M, Chiang GG et al (2002) Regulation of hypoxia-inducible factor 1 \u03b1 expression and function by the mammalian target of rapamycin. Mol Cell Biol 22(20):7004\u20137014","journal-title":"Mol Cell Biol"},{"issue":"24","key":"226_CR3","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","volume":"102","author":"CM Johannessen","year":"2005","unstructured":"Johannessen CM, Reczek EE, James MF et al (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci 102(24):8573\u20138578","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"226_CR4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","volume":"28","author":"E Missiaglia","year":"2010","unstructured":"Missiaglia E, Dalai I, Barbi S et al (2010) Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28(2):245\u2013255","journal-title":"J Clin Oncol"},{"issue":"12","key":"226_CR5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1055\/s-0031-1291333","volume":"43","author":"M Krausch","year":"2011","unstructured":"Krausch M, Raffel A, Anlauf M et al (2011) Loss of PTEN expression in neuroendocrine pancreatic tumors. Horm Metab Res 43(12):865\u2013871","journal-title":"Horm Metab Res"},{"issue":"6","key":"226_CR6","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0002-9440(10)65495-8","volume":"155","author":"EJM Speel","year":"1999","unstructured":"Speel EJM, Richter J, Moch H et al (1999) Short communication genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 155(6):1787\u20131794","journal-title":"Am J Pathol"},{"issue":"1","key":"226_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cancergencyto.2004.04.015","volume":"156","author":"G Floridia","year":"2005","unstructured":"Floridia G, Grilli G, Salvatore M et al (2005) Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors. Cancer Genet Cytogenet 156(1):23\u201330","journal-title":"Cancer Genet Cytogenet"},{"issue":"4","key":"226_CR8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1947601910371979","volume":"1","author":"W Hu","year":"2010","unstructured":"Hu W, Feng Z, Modica I et al (2010) Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer 1(4):360\u2013368","journal-title":"Genes Cancer"},{"issue":"6021","key":"226_CR9","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","volume":"331","author":"Y Jiao","year":"2011","unstructured":"Jiao Y, Shi C, Edil BH et al (2011) DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021):1199\u20131203","journal-title":"Science"},{"issue":"29","key":"226_CR10","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1200\/JCO.2005.05.5194","volume":"24","author":"C Roldo","year":"2006","unstructured":"Roldo C, Missiaglia E, Hagan JP et al (2006) MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 24(29):4677\u20134684","journal-title":"J Clin Oncol"},{"issue":"2","key":"226_CR11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.gastro.2007.05.022","volume":"133","author":"F Meng","year":"2007","unstructured":"Meng F, Henson R, Wehbe-Janek H et al (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2):647\u2013658","journal-title":"Gastroenterology"},{"key":"226_CR12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/annonc\/mdr048","volume":"23","author":"V Corbo","year":"2012","unstructured":"Corbo V, Beghelli S, Bersani S et al (2012) Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Ann Oncol 23:127\u2013134","journal-title":"Ann Oncol"},{"key":"226_CR13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514\u2013523","journal-title":"N Engl J Med"},{"issue":"5","key":"226_CR14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1073\/pnas.0510772103","volume":"103","author":"S Kang","year":"2006","unstructured":"Kang S, Denley A, Vanhaesebroeck B, Vogt PK (2006) Oncogenic transformation induced by the p110 \u03b2, -\u03b3, and -\u03b4 isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci 103(5):1289\u20131294","journal-title":"Proc Natl Acad Sci"},{"key":"226_CR15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-9966-29-32","volume":"29","author":"S Barbi","year":"2010","unstructured":"Barbi S, Cataldo I, De Manzoni G et al (2010) The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 29:32","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"226_CR16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627\u2013644","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"226_CR17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jamcollsurg.2009.03.006","volume":"209","author":"SC Pitt","year":"2010","unstructured":"Pitt SC, Chen H, Kunnimalaiyaan M et al (2010) Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg 209(1):82\u201388","journal-title":"J Am Coll Surg"},{"issue":"1","key":"226_CR18","first-page":"336","volume":"178","author":"C Couderc","year":"2011","unstructured":"Couderc C, Poncet G, Villaume K et al (2011) Targeting the PI3K\/mTOR pathway in murine endocrine cell lines in vitro and in vivo effects on tumor cell growth. AJPA 178(1):336\u2013344","journal-title":"AJPA"},{"issue":"1","key":"226_CR19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2010.02.018","volume":"295","author":"K Zitzmann","year":"2010","unstructured":"Zitzmann K, R\u00fcden JV, Brand S et al (2010) Compensatory activation of Akt in response to mTOR and Raf inhibitors\u2014a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 295(1):100\u2013109","journal-title":"Cancer Lett"},{"issue":"9","key":"226_CR20","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-feldstein J et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Investig 118(9):3065\u20133074","journal-title":"J Clin Investig"},{"issue":"3","key":"226_CR21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","volume":"13","author":"B Vanhaesebroeck","year":"2012","unstructured":"Vanhaesebroeck B, Stephens L, Hawkins P (2012) PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 13(3):195\u2013203","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"50","key":"226_CR22","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50):7455\u20137464","journal-title":"Oncogene"},{"issue":"7052","key":"226_CR23","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/436792a","volume":"436","author":"DW Parsons","year":"2005","unstructured":"Parsons DW, Wang T-L, Samuels Y et al (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436(7052):792","journal-title":"Nature"},{"issue":"2","key":"226_CR24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccr.2007.07.014","volume":"12","author":"J Brugge","year":"2007","unstructured":"Brugge J, Hung M-C, Mills GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer Cell 12(2):104\u2013107","journal-title":"Cancer Cell"},{"issue":"42","key":"226_CR25","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1038\/onc.2008.170","volume":"27","author":"FE Bleeker","year":"2008","unstructured":"Bleeker FE, Felicioni L, Buttitta F et al (2008) AKT1(E17K) in human solid tumours. Oncogene 27(42):5648\u20135650","journal-title":"Oncogene"},{"issue":"12","key":"226_CR26","first-page":"5063","volume":"30","author":"M Ghayouri","year":"2010","unstructured":"Ghayouri M, Boulware D, Nasir A et al (2010) Activation of the serine\/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. Anticancer Res 30(12):5063\u20135067","journal-title":"Anticancer Res"},{"issue":"5","key":"226_CR27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2826.2006.01425.x","volume":"18","author":"J Shah","year":"2006","unstructured":"Shah J, Hochhauser D, Frow R et al (2006) Epidermal growth factor receptor and activation in neuroendocrine tumors. J Neuroendocrinol 18(5):355\u2013360","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"226_CR28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1530\/ERC-12-0074","volume":"19","author":"K Zitzmann","year":"2012","unstructured":"Zitzmann K, Vlotides G, Brand S et al (2012) Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Endocr Relat Cancer 19(3):423\u2013434","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"226_CR29","first-page":"876","volume":"40","author":"CR Gloesenkamp","year":"2012","unstructured":"Gloesenkamp CR, Nitzsche B, Ocker M et al (2012) AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. Int J Oncol 40(3):876\u2013888","journal-title":"Int J Oncol"},{"issue":"35","key":"226_CR30","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","volume":"29","author":"TA Yap","year":"2011","unstructured":"Yap TA, Yan L, Patnaik A et al (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29(35):4688\u20134695","journal-title":"J Clin Oncol"},{"issue":"67","key":"226_CR31","doi-asserted-by":"crossref","first-page":"pe27","DOI":"10.1126\/scisignal.267pe27","volume":"2","author":"DR Alessi","year":"2009","unstructured":"Alessi DR, Pearce LR, Garc\u00eda-Mart\u00ednez JM (2009) New insights into mTOR signaling: mTORC2 and beyond. Sci Signal 2(67):pe27","journal-title":"Sci Signal"},{"issue":"2","key":"226_CR32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200403069","volume":"166","author":"LS Harrington","year":"2004","unstructured":"Harrington LS, Findlay GM, Gray A et al (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166(2):213\u2013223","journal-title":"J Cell Biol"},{"issue":"18","key":"226_CR33","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cub.2004.08.026","volume":"14","author":"OJ Shah","year":"2004","unstructured":"Shah OJ, Wang Z, Hunter T (2004) Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14(18):1650\u20131656","journal-title":"Curr Biol"},{"issue":"41","key":"226_CR34","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1038\/onc.2008.247","volume":"27","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Pandolfi PP (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27(41):5527\u20135541","journal-title":"Oncogene"},{"issue":"18","key":"226_CR35","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1002\/cncr.26011","volume":"117","author":"B Svejda","year":"2011","unstructured":"Svejda B, Kidd M, Kazberouk A et al (2011) Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1\/2 and AKT. Cancer 117(18):4141\u20134154","journal-title":"Cancer"},{"issue":"2","key":"226_CR36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2443.2010.01482.x","volume":"16","author":"M Hardt","year":"2011","unstructured":"Hardt M, Chantaravisoot N, Tamanoi F et al (2011) Activating mutations of TOR (target of rapamycin). Genes Cells 16(2):141\u2013151","journal-title":"Genes Cells"},{"issue":"67","key":"226_CR37","doi-asserted-by":"crossref","first-page":"pe24","DOI":"10.1126\/scisignal.267pe24","volume":"2","author":"DA Guertin","year":"2009","unstructured":"Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2(67):pe24","journal-title":"Sci Signal"},{"issue":"19","key":"226_CR38","doi-asserted-by":"crossref","first-page":"14071","DOI":"10.1074\/jbc.R109.094003","volume":"285","author":"KG Foster","year":"2010","unstructured":"Foster KG, Fingar DC (2010) Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285(19):14071\u201314077","journal-title":"J Biol Chem"},{"issue":"1","key":"226_CR39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000100057","volume":"85","author":"K Zitzmann","year":"2007","unstructured":"Zitzmann K, De Toni EN, Brand S et al (2007) The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85(1):54\u201360","journal-title":"Neuroendocrinology"},{"issue":"3","key":"226_CR40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000111501","volume":"87","author":"S Grozinsky-Glasberg","year":"2008","unstructured":"Grozinsky-Glasberg S, Franchi G, Teng M et al (2008) Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 87(3):168\u2013181","journal-title":"Neuroendocrinology"},{"issue":"3","key":"226_CR41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1677\/ERC-10-0097","volume":"17","author":"MC Zatelli","year":"2010","unstructured":"Zatelli MC, Minoia M, Martini C et al (2010) Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer 17(3):719\u2013729","journal-title":"Endocr Relat Cancer"},{"issue":"16","key":"226_CR42","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","volume":"18","author":"F Meric-Bernstam","year":"2012","unstructured":"Meric-Bernstam F, Akcakanat A, Chen H et al (2012) PIK3CA\/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 18(16):1777\u20131789","journal-title":"Clin Cancer Res"},{"issue":"1","key":"226_CR43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28(1):69\u201376","journal-title":"J Clin Oncol"},{"issue":"9808","key":"226_CR44","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005\u20132012","journal-title":"Lancet"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-012-0226-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-012-0226-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-012-0226-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T16:15:10Z","timestamp":1559405710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-012-0226-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,14]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["226"],"URL":"https:\/\/doi.org\/10.1007\/s11523-012-0226-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,14]]}}}